OTCQX:MRVFF - Post by User
Comment by
geos571on Feb 11, 2015 11:12am
154 Views
Post# 23418072
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Even if
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Even if This isnt bull ..... this is fact
Regulatory authorities, such as the FDA and EMA, recommend the use of ACCs in drug development to evaluate the optimal dose and onset of action during early clinical development. In combination with natural-exposure Phase III studies, they provide supportive evidence of superiority over placebo as an additional pharmacodynamic assessment tool. In particular, ACC studies may be of additional value in the clinical development of immunotherapy, because the variability of natural allergen exposure hampers the demonstration of efficacy in clinical trials.
Read more at https://www.stockhouse.com/companies/bullboard/t.nri/nuvo-research-inc#l1qdj0QbhtdGRo5Z.99